Chlamydia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Chlamydial infection, caused by Chlamydia trachomatis (C. trachomatis (Ct)), is the most common bacterial STI and results in most serious infections, including Pelvic Inflammatory Disease (PID), ectopic pregnancy, and infertility in women. Occurring most commonly among young sexually active adults, C. trachomatis causes cervicitis in women, urethritis in men, and extra-genital infections, including rectal and oropharyngeal infections. Asymptomatic infections are common in both men and women. Untreated chlamydial infection may cause severe complications in the upper reproductive tract, primarily in young women, including ectopic pregnancy, salpingitis and infertility. Lymphogranuloma venereum (LGV), caused by a more invasive serovar of C. trachomatis, is increasingly prevalent among men do sex with men. Maternal infection is associated with severe adverse outcomes in neonates, such as preterm birth, low birth weight, conjunctivitis, nasopharyngeal infection, and pneumonia. C. trachomatis can be diagnosed by culture.
·
The incidence of Chlamydial infection (CI)
ranges from 335 to 550 cases per 100,000 population in the USA.
Thelansis’s “Chlamydia Market Outlook,
Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To
2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Chlamydia treatment modalities options for
eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Chlamydia across 8 MM market from the centre of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Chlamydia Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment